QuickView for CACNA1H;jsessionid=D4884D264F989B51601A1791B109E9B9;jsessionid=97768875D1A852069DFFB01DE8231909;jsessionid=5AF62B14C366251FF1F3720EE484FCAB;jsessionid=C7EC49B8ECE4B7644082EF287D22E79C;jsessionid=50D9349CBF42798B6BA8B89730ECA68E;jsessionid=C6FDDB5946D30A2A808FABCFA0AFD896;jsessionid=003E1134197995EBCF349BBCF806D4D1;jsessionid=6BC95536132CDBB4A94D8F13151F1627;jsessionid=121061F1294A5BFEC1CDF54AE03CEC70;jsessionid=C5C41C8850B7062D44CD0E9409AC82DD (gene)

1. CaV3.2 (CACNA1H) in Primary Aldosteronism.
2. A Novel Somatic Mutation of CACNA1H p.V1937M in Unilateral Primary Hyperaldosteronism.
3. Targeting T-type/CaV3.2 channels for chronic pain.
4. Adiponectin receptor 1-mediated stimulation of Cav3.2 channels in trigeminal ganglion neurons induce…
5. The T-type calcium channel CaV3.2 regulates insulin secretion in the pancreatic β-cell.

There were no clinical trials for CACNA1H;jsessionid=D4884D264F989B51601A1791B109E9B9;jsessionid=97768875D1A852069DFFB01DE8231909;jsessionid=5AF62B14C366251FF1F3720EE484FCAB;jsessionid=C7EC49B8ECE4B7644082EF287D22E79C;jsessionid=50D9349CBF42798B6BA8B89730ECA68E;jsessionid=C6FDDB5946D30A2A808FABCFA0AFD896;jsessionid=003E1134197995EBCF349BBCF806D4D1;jsessionid=6BC95536132CDBB4A94D8F13151F1627;jsessionid=121061F1294A5BFEC1CDF54AE03CEC70;jsessionid=C5C41C8850B7062D44CD0E9409AC82DD